Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression

SIMPLE SUMMARY: Nucleolin (NCL) regulates tumour growth and angiogenesis, and its inhibition normalizes tumour vessels and impairs pancreatic ductal adenocarcinoma (PDAC) growth. Since tumour vessel normalization promotes immunostimulatory reprogramming, we investigated the effects of a selective in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponzo, Matteo, Debesset, Anais, Cossutta, Mélissande, Chalabi-Dchar, Mounira, Houppe, Claire, Pilon, Caroline, Nicolas-Boluda, Alba, Meunier, Sylvain, Raineri, Fabio, Thiolat, Allan, Nicolle, Rémy, Maione, Federica, Brundu, Serena, Cojocaru, Carina Florina, Bouvet, Philippe, Bousquet, Corinne, Gazeau, Florence, Tournigand, Christophe, Courty, José, Giraudo, Enrico, Cohen, José L., Cascone, Ilaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454580/
https://www.ncbi.nlm.nih.gov/pubmed/36077801
http://dx.doi.org/10.3390/cancers14174265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454580/
https://www.ncbi.nlm.nih.gov/pubmed/36077801
http://dx.doi.org/10.3390/cancers14174265

Ejemplares similares